CCN2 and scleroderma: Furthermore, our data suggest a direct role for TGM2 as selective inhibition using BB7, an antibody directed toward the catalytic core of TGM2,28 which reverses the scleroderma phenotype, reduced the expression of Col‐1, CCN2, fibronectin, and αSMA.